Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSIW) Accumulated Expenses (2022 - 2025)

TriSalus Life Sciences' Accumulated Expenses history spans 4 years, with the latest figure at $8.1 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 10.07% year-over-year to $8.1 million; the TTM value through Dec 2025 reached $8.1 million, up 10.07%, while the annual FY2025 figure was $8.1 million, 10.07% up from the prior year.
  • Accumulated Expenses reached $8.1 million in Q4 2025 per TLSIW's latest filing, up from $6.8 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $11.4 million in Q1 2024 to a low of $6.4 million in Q4 2022.
  • Average Accumulated Expenses over 4 years is $8.2 million, with a median of $7.9 million recorded in 2024.
  • Peak YoY movement for Accumulated Expenses: skyrocketed 65.53% in 2023, then plummeted 30.32% in 2024.
  • A 4-year view of Accumulated Expenses shows it stood at $6.4 million in 2022, then surged by 65.53% to $10.6 million in 2023, then crashed by 30.32% to $7.4 million in 2024, then increased by 10.07% to $8.1 million in 2025.
  • Per Business Quant, the three most recent readings for TLSIW's Accumulated Expenses are $8.1 million (Q4 2025), $6.8 million (Q3 2025), and $7.1 million (Q2 2025).